Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Ovarian Cancer · Serous Ovarian Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Contact: Study coordinator (Sarah M Lynam, MD) · Sarah.Lynam@UHhospitals.org · 800-641-2422

Study leads

Sarah Lynam, MD
Principal Investigator
Case Comprehensive Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Breast Cancer · Endometrial Cancer · Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Orlando, United States · Boston, United States

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Chicago, United States · Kelowna, Canada

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer

Abroad (travel likely)RecruitingPHASE2

Hefei, China · Beijing, China

Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer

Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Xuzhou, China